Menu

Parkinson’s Researcher Notches 17 Retracted Papers

Scientific misconduct motivated Yoshihiro Sato’s three additional retractions last month; his institution doesn’t respond. 

Sep 13, 2017
Aggie Mika

ISTOCK, ALLANSWARTUpdate (December 7, 2017): According to Retraction Watch, Sato’s retraction count is now up to 23 and Hirosaki University, where Sato was based from 2000 to 2003, confirmed in November that a number of Sato’s papers were compromised by fake data, plagiarism, or authorship issues.

Yoshihiro Sato, a researcher from Mitate Hospital in Tagawa, Japan, cited scientific wrongdoing when he asked the Journal of Neurology, Neurosurgery, and Psychiatry to pull three of his publications, adding to his list of 14 prior retractions, Retraction Watch reports.

The journal announced its investigation in May and retracted Sato’s three papers last month. According to the retraction notices, Sato told the journal editors that he didn’t have his coauthors’ permission to include them on the papers and that the authors in question didn’t contribute to the published science.

“Despite repeated requests for further explanation, we have not received any response from Dr Sato’s institution,” read the journal’s retraction notices

The now-disputed research involves randomized human studies testing various therapeutics for ailments associated with Parkinson’s Disease. The most-cited study of the three, published in 1999, garnered 79 citations and reported that a form of vitamin D could lessen the risk for bone fractures in Parkinson’s patients with low bone density. The other two studies were published in 2003 and 2011 and cited 28 and eight times, respectively, reports Retraction Watch.

In addition to the mounting list of retractions, more of Sato’s papers have recently come under fire. Last year, a group of researchers investigated the validity of 33 human trials that list Sato as an author and determined that the studies were suspect.

“Our analysis suggests that the results of at least some of these trials are not reliable,” investigation coauthor Mark Bolland of the University of Auckland told Across America Patch in 2016. “In addition, results from these trials were not consistent with results found in similar studies by other researchers.”

The journals that retracted Sato’s work in the past report a laundry list of reasons, ranging from plagiarism to authorship mishaps, notes the Retraction Watch report.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.